Viking Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw major clinical progress with VK2735 in both injectable and oral forms, completion of key trial enrollments, and expanded maintenance dosing studies. R&D expenses surged, driving a higher net loss, but cash reserves remain strong, supporting operations into 2028.
-
Phase III trials for dual agonist VK2735 are progressing rapidly, with key data readouts and a maintenance study expected in Q3 2026. The company is leveraging a differentiated product profile, efficient trial design, and a flexible commercial strategy to compete in a segmented obesity market.
-
Lead dual agonist VK2735 is advancing in both oral and sub-Q forms, showing strong, durable weight loss and good tolerability in phase II studies. Phase III VANQUISH trials are underway, with data expected in 2027, and maintenance dosing strategies are a focus. Strategic and licensing interest in the pipeline remains high.
Fiscal Year 2025
-
Multiple clinical milestones achieved in 2025, including advancing both subcutaneous and oral VK2735 into late-stage trials, with strong efficacy and safety data. Net loss increased due to higher R&D spend, but cash reserves remain strong to fund upcoming Phase III trials and new programs.
-
Lead obesity drug VK2735, in both oral and subQ forms, showed strong, dose-dependent weight loss and good tolerability in phase II trials. Phase III studies are underway, with key data and regulatory meetings expected over the next year.
-
Positive Phase 2 results for oral VK2735 showed significant weight loss and strong safety, while Phase 3 VANQUISH trials are enrolling ahead of schedule. Cash reserves of $715M support ongoing development, with key regulatory milestones and new maintenance dosing studies expected in 2026.
-
Lead obesity drug VK2735 is advancing in both oral and subcutaneous forms, showing strong weight loss and tolerability in phase II and III trials. The company is leveraging a lean model and direct-to-patient channels, with ample cash to support development and a focus on efficacy and future combination therapies.
-
Multiple phase III obesity trials are progressing with strong enrollment and promising efficacy, including up to 12.2% weight loss in oral studies. Manufacturing partnerships ensure robust supply, and financial resources are sufficient for ongoing development. Flexible dosing and maintenance strategies aim to improve patient outcomes and margins.
-
The phase II Venture Oral Dosing Study of VK2735 met primary and secondary endpoints, showing up to 12.2% mean body weight reduction and strong safety/tolerability over 13 weeks. Maintenance dosing and lower titration rates are expected to optimize efficacy and minimize GI side effects.
-
Advanced VK2735 obesity program with phase III trials underway and phase II oral study enrollment completed. Q2 net loss widened to $65.6M on higher R&D and G&A expenses, with $808M in cash supporting ongoing development. Top-line phase II oral data and amylin IND filing expected in H2 2025.
-
VK2735, a dual GLP-1/GIP agonist, showed robust, durable weight loss in phase II and is advancing to phase III, with both injectable and oral formulations under development. Manufacturing and supply are secured for large-scale commercialization, and strategic partnering remains a key focus.
-
Q1 2025 saw major clinical and operational progress, including advancing VK2735 to Phase III, rapid Phase II oral trial enrollment, and a strong cash position to fund development. Net loss increased due to higher R&D and G&A expenses, but market enthusiasm for obesity programs remains high.
-
Lead obesity program VK2735 is advancing to phase 3 with both subQ and oral forms, supported by a major supply agreement with CordenPharma. Phase 2 data show strong efficacy and tolerability, and the company is well-funded to support multi-year development.
-
Lead metabolic programs are advancing, with VK2735 showing strong efficacy and tolerability in both sub-Q and oral forms. Phase III trials are set for 2024, supported by robust financials and strategic supply planning. Licensing and partnership discussions are ongoing.
Fiscal Year 2024
-
Reported strong clinical progress in obesity, MASH, and XALD programs, with significant weight loss and safety data for VK2735. Ended 2024 with $903M in cash, supporting upcoming Phase 3 trials and new program launches.
-
Injectable and oral dual agonist therapies offer flexible, durable weight loss with strong tolerability and maintenance options. Manufacturing scale-up is underway, and competitive advantages include formulation flexibility and potential for combination therapies. Recent data has attracted positive industry attention.
-
Reported strong Q3 and nine-month financials with increased R&D and G&A expenses, supported by a robust $930M cash position. Advanced four clinical programs, including VK2735 for obesity and VK2809 for NASH, all meeting key endpoints, and outlined plans for phase 3 and new pipeline assets.
-
Lead obesity programs are advancing, with SubQ formulation moving to phase III and oral formulation showing promising early results. Regulatory feedback supports accelerated development, and manufacturing and financial resources are in place for late-stage trials.
-
Strong clinical progress in obesity and NASH programs, with VK2735 and VK2809 showing best-in-class efficacy and safety. Cash reserves of $942M support advancement into phase III and new pipeline programs, with key regulatory meetings and trial initiations planned for late 2024.
-
Recent clinical data show strong efficacy and safety for both NASH and obesity programs, with VK2809 achieving significant NASH resolution and fibrosis improvement, and VK2735 delivering robust, dose-dependent weight loss in both subcutaneous and oral forms. $960 million in cash supports ongoing and future trials.
-
The 52-week phase IIb VOYAGE trial showed VK2809 achieved significant improvements in NASH resolution, fibrosis, and liver fat reduction, with robust safety and tolerability. Efficacy was consistent across subgroups, and the drug demonstrated potential cardiovascular benefits.